This study is an observational study designed to obtain information on the long-term safety, tolerability, and continued activity of Q-Cells®. The study will follow the participants who previously received Q-Cells® for 10 years. The goal of this observational study is to learn about the long term effects of Q-Cells® in people with transverse myelitis. The main objectives the study is to evaluate the safety of patients who have received Q-Cells®. The secondary goal of the study is to get data about the long-term activity of Q-Cells® over a period of 10 years. Patients will complete exams, lab tests, imaging, and questionnaires to monitor their safety.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Adverse Events
Timeframe: through study completion, an average of 10 years
Safety: Vital signs: Systolic Blood Pressure
Timeframe: through study completion, an average of 10 years
Safety Endpoints: Vital signs: Diastolic Blood Pressure
Timeframe: through study completion, an average of 10 years
Safety Endpoints: Vital signs: Pulse
Timeframe: through study completion, an average of 10 years
Safety Endpoints: Vital signs: Temperature
Timeframe: through study completion, an average of 10 years
Safety as measured by change in Electrocardiogram (ECG) measures from baseline at 10 years
Timeframe: through study completion, an average of 10 years (Baseline, 10 years)
Safety Endpoints: Clinical Laboratory assessments: chemistry
Timeframe: through study completion, an average of 10 years
Safety Endpoints: Clinical Laboratory assessments: hematology
Timeframe: through study completion, an average of 10 years